Keymeulen, Kristien B. I. M. http://orcid.org/0000-0001-5992-7087
Geurts, Sandra M. E.
Kooreman, Loes F. S.
Duijm, Lucien E. M.
Engelen, Sanne
Vanwetswinkel, Sigrid
Luiten, Ernest
Siesling, Sabine
Voogd, Adri C.
Tjan-Heijnen, Vivianne C. G.
Funding for this research was provided by:
KWF Kankerbestrijding (2013-6486)
Article History
Received: 25 March 2022
Revised: 1 July 2022
Accepted: 16 August 2022
First Online: 30 September 2022
Declarations
:
: The scientific guarantor of this publication is Prof. Vivianne C.G. Tjan-Heijnen, MD, PhD.
: The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.Potential conflicts of interest <i>not</i> related to the subject of this article: SG reports grants from Roche, Pfizer, Novartis, Eli Lilly, Daiichi Sankyo and Gilead, and personal fees from AstraZeneca. All outside the submitted work, VT-H reports grants and personal fees from Roche, Novartis, Pfizer and Eli Lilly, and grants from AstraZeneca, Eisai, Daiichi Sankyo and Gilead.
: One of the authors has significant statistical expertise.
: Written informed consent was waived by the Institutional Review Board.
: Institutional Review Board approval was not required because anonymised data from the Netherlands Cancer Registry are used.
: Some study subjects or cohorts have been previously reported in Br J Surg. 2019;106(11): 1488-1494.doi: 10.1002/bjs.11299.
: • retrospective• observational• multicentre study